港股异动 | 和黄医药(00013)现跌超4% 24年收入略逊于预期 机构称25年财政年度收入目标保守

智通财经
25 Mar

智通财经APP获悉,和黄医药(00013)现跌超4%,截至发稿,跌4.59%,报22.85港元,成交额5727.95万港元。

瑞银发布研报称,和黄医药去年收入同比跌43%,略逊于预期;净利润3820万美元,胜于该行及市场分别预期的净亏损3,720万及1,850万美元。瑞银表示,乐见和黄医药在销售增长及效率改善的带动下,提早一年实现可持续的收支平衡。该行将集团目标价由38.7港元下调至37.7港元。

招银国际发表报告指,预期FRUZAQLA的海外销售将持续保持强劲势头,对公司2025年3.5亿至4.5亿美元的肿瘤业务目标充满信心,并预计其合并产品组合在2025财政年度的市场销售将按年增长35%。配合公司保守的2025财政年度收入目标,该行亦调整收入预测,目标价由35.61元修订为34.03元。维持“买入”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10